News Sentiment

AZN sentiment intelligence

AstraZeneca PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 58 Balanced news tone 61 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 174.93 Week of 19 Jun 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 16

high-authority source matches

Trend context Trend inactive

-2.1% over one week, -6.5% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today

Market Reaction

Balanced read

69/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -2.1% Price reacting lower
Trend fit Trend inactive -6.5% over four weeks
Fair value 18.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 27
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Reuters 6
MarketWatch 5
TradingView 3
www.marketscreener.com 3
Benzinga 3
AstraZeneca 3
Stock Titan 2

Event Lens

What the news is about

Classified themes
Market update 40
Regulatory and legal 7
Earnings 7
Balance sheet 2
Analyst action 2
Guidance 1
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
FirstWord Pharma Direct company coverage

AstraZeneca unveils data behind Phase III-bound oral GLP-1

AstraZeneca has unveiled data supporting its Phase III-bound oral GLP-1 receptor agonist, danuglipron. The company is positioning danuglipron as a potential strong competitor in the rapidly growing obesity and diabetes market. This oral GLP-1 is expected to enter late-stage clini

Tone
Positive 66/100
Event
Market update
Published
08 Jun 2026 20:40
Source
FirstWord Pharma
Bloomberg.com Direct company coverage

Astra Obesity Pill Delivers 11.8% Weight Loss in Mid-Stage Trial

AstraZeneca's experimental obesity pill, elecoglipron, demonstrated an 11.8% body weight loss in a mid-stage clinical trial. This positions AstraZeneca to enter the growing weight-loss drug market, though its pill showed less efficacy compared to rival drugs from Eli Lilly and No

Tone
Positive 66/100
Event
Market update
Published
08 Jun 2026 20:15
Source
Bloomberg.com
Benzinga Direct company coverage

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

AstraZeneca's Ultomiris (ravulizumab) has demonstrated a significant and early reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN) at risk of disease progression, according to interim results from the Phase 3 I CAN trial. Patients treated with Ultomiris ex

Tone
Positive 65/100
Event
Earnings
Published
08 Jun 2026 16:40
Source
Benzinga
MarketWatch Direct company coverage

AstraZeneca advances Friday, outperforms market

AstraZeneca PLC (AZN) shares advanced 2.24% to £138.58 on Friday, outperforming the FTSE 100 Index. The increase occurred during a favorable trading session, with the FTSE 100 rising 0.07%. AstraZeneca's closing price was 11.91% below its 52-week high.

Tone
Positive 74/100
Event
Market update
Published
05 Jun 2026 12:06
Source
MarketWatch
MarketWatch Direct company coverage

AstraZeneca advances Thursday, outperforms market

AstraZeneca PLC shares rose 2.60% to £135.54 on Thursday, outperforming the broader market as the FTSE 100 Index also saw a modest rise. The company's stock closed 13.84% below its 52-week high of £157.32, which was reached in February. This performance occurred on an overall pos

Tone
Positive 71/100
Event
Market update
Published
04 Jun 2026 12:06
Source
MarketWatch
TradingView Direct company coverage

Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?

AstraZeneca's oncology segment, contributing 44% of total product sales, is a primary growth driver, with strong demand for drugs like Tagrisso, Lynparza, and Enhertu. The company is strengthening its portfolio through label expansions and advancing a deep late-stage pipeline, in

Tone
Positive 70/100
Event
Macro sensitivity
Published
03 Jun 2026 22:09
Source
TradingView
Proactive financial news Direct company coverage

Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions

Deutsche Bank has reiterated its "sell" rating and 11,500p price target for AstraZeneca, despite positive data presented at the ASCO conference. The bank acknowledges AstraZeneca's strong oncology record but remains cautious due to unresolved questions regarding regulatory approv

Tone
Negative 36/100
Event
Analyst action
Published
03 Jun 2026 20:32
Source
Proactive financial news